Clinical Characteristics and Treatment Outcomes of Non-anaplastic Peripheral T-Cell Lymphoma in Children and Adolescents: A Single-center Experience

다국어 초록 (Multilingual Abstract)

Background: Peripheral T-cell lymphoma (PTCL) is a rare form of non-Hodgkin’s lymphoma (NHL), and it is usually associated with poor outcome. Here, we report our experience in treating this disease over 19 years, with the aim of helping to establish better treatment methods.
Methods: We retrospectively investigated 18 non-anaplastic PTCL cases that were diagnosed at a medical center in Seoul between October 1995 and October 2014. The clinical characteristics, treatments, and outcomes were reviewed.
Results: According to the World Health Organization (WHO) classifications for PTCL, 11 patients had PTCL, not otherwise specified (PTCL-NOS), 6 patients had extranodal natural killer/T-cell lymphoma, nasal type (ENKL), and 1 patient had subcutaneous panniculitis-like T-cell lymphoma. Patients were treated with various chemotherapeutic regimens. Of these 18 patients, 5 (27.7%) relapsed and 7 (38.9%) died from disease progression. Two relapsed patients received high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HDCT-ASCT). The 5-year event-free and overall survival rates were 43.2% and 66.7% in all cases, 45.5% and 54.5% in PTCL-NOS, and, 25.0% and 83.3% in ENKL, respectively.
Conclusion: PTCL-NOS showed a suboptimal outcome. Among 6 ENKL patients, 3 relapsed, but 2 of 3 relapsed patients were salvaged. For better prognosis, HDCT-ASCT in relapsing and refractory PTCL and chemo-radiotherapy in ENKL could be considered as a salvage treatment. Larger studies are needed to confirm the outcome. Furthermore, an effort should be made to develop more efficient initial therapies through collaborative research.

참고문헌 (Reference)

1 Savage KJ, "Update: peripheral T-cell lymphomas" 6 : 222-230, 2011

2 Foss FM., "Treatment strategies for peripheral T-cell lymphomas" 26 : 43-56, 2013

3 조은윤, "The Spectrum of Epstein-Barr Virus-Associated Lymphoproliferative Disease in Korea: Incidence of Disease Entities by Age Groups" 대한의학회 23 (23): 185-192, 2008

4 Kobayashi R, "Stem cell transplantation for paediatric patients with non-anaplastic peripheral T-cell lymphoma in Japan" 159 : 88-93, 2012

5 Kobayashi R, "Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan" 54 : 212-215, 2010

6 Wang ZY, "Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents" 114 : 4771-4776, 2009

7 Gallamini A, "Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study" 103 : 2474-2479, 2004

8 Al Mahmoud R, "Peripheral T-cell lymphoma in children and adolescents: a single-institution experience" 34 : 611-616, 2012

9 Windsor R, "Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years" 50 : 784-787, 2008

10 Park S, "Peripheral T cell lymphoma in Asia" 99 : 227-239, 2014

11 Gaulard P, "Pathology of peripheral T-cell lymphomas:where do we stand?" 51 : 5-16, 2014

12 Hutchison RE, "Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Children's Oncology Group study" 51 : 29-33, 2008

13 Kontny U, "Non-anaplastic peripheral T-cell lymphoma in children and adolescents-a retrospective analysis of the NHL-BFM study group" 168 : 835-844, 2015

14 Lai C, "NK/T-cell lymphomas in children" 26 : 33-41, 2013

15 Kim TM, "Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type" 106 : 3785-3790, 2005

16 Lowe EJ, "Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941" 52 : 335-339, 2009

17 Dearden CE, "Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)" 153 : 451-485, 2011

18 Jaffe ES, "Extranodal peripheral T-cell and NK-cell neoplasms" 111 (111): S46-S55, 1999

19 Lee J, "Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study" 24 : 612-618, 2006

20 Jaccard A, "Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study" 117 : 1834-1839, 2011

21 Asselin BL, "Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404)" 118 : 874-883, 2011

22 Cheung MM, "Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality" 54 : 182-190, 2002

23 Wang C, "Curative effect of nasal type extranodal NK/T-cell lymphoma by sequential chemotherapy combined radiotherapy compared with chemotherapy" 27 : 1283-1286, 2013

24 Kim SJ, "Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma:CISL08-01 phase II study" 93 : 1895-1901, 2014

25 Yuan F, "A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma" 35 : 614-618, 2014